A Clinical Study of Ultra-transplantation for the Treatment of Major Thalassemia Scheme
Recruiting now · Not applicable
Conditions studied: Stem Cell Transplantation
In brief
Yunnan is a high-incidence area of Eastern Mediterranean (thalassemia) in China, and the treatment cost of thalassemia patients is high, hematopoietic stem cell transplantation (HSCT) is the only means to cure thalassemia, but there are problems in donor screening and the risk of complications. Professor Ai Huisheng's team proposed a new concept of hypertransplantation, which does not require pretreatment and has no risk of GVHD, and animal experiments have shown good efficacy. Under the guidance of Professor Ai, the center plans to carry out clinical research on hypertransplantation and explore safe and effective new therapies for thalassemia.
Key facts
- Study ID
- NCT06743477
- Run by
- Hu Peng
- People needed
- 5
- Starts
- 2025-08-29
- Expected to finish
- 2026-12-31
- Last updated by the study team
- 2025-09-02
Who can join
Age: 7 and older, up to 12. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Yunnan First People's Hospital — Kunming, Yunnan, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.